Executive Officers

Blaise Coleman

Blaise_Coleman.jpgBlaise Coleman was appointed President and Chief Executive Officer and a member of the Board of Directors, effective March 2020. He previously served Executive Vice President and Chief Financial Officer since December 2016. He joined Endo in January 2015 as Vice President of Corporate Financial Planning & Analysis, and was then promoted to Senior Vice President, Global Finance Operations in November 2015. He also served as Endo’s Interim Chief Financial Officer. Prior to joining Endo, Mr. Coleman held a number of finance leadership roles with AstraZeneca, a global biopharmaceutical company, most recently as the Chief Financial Officer of the AstraZeneca/Bristol-Myers Squibb US Diabetes Alliance. Prior to that, he was the Head of Finance for the AstraZeneca Global Medicines Development organization based in Mölndal, Sweden. Mr. Coleman joined AstraZeneca in 2007 as Senior Director Commercial Finance for the US Cardiovascular Business. He joined AstraZeneca from Centocor, a wholly owned subsidiary of Johnson & Johnson, where he held positions in both the Licenses & Acquisitions and Commercial Finance organizations. Mr. Coleman's move to Centocor in early 2003 followed 7 years' experience with the global public accounting firm, PricewaterhouseCoopers LLP. Mr. Coleman is a Certified Public Accountant; he holds a Bachelor of Science degree in accounting from Widener University and an M.B.A. from the Fuqua School of Business at Duke University.

Patrick Barry

Patrick BarryPatrick Barry was appointed Executive Vice President and President, Global Commercial Operations effective April 2020.  In this role, he has responsibility for the Company’s global commercial organization across each of Endo’s four reportable business segments, including Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. He formerly served as Executive Vice President and Chief Commercial Officer, U.S. Branded Business since February 2018, after joining Endo in December 2016 as Senior Vice President, U.S. Branded Pharmaceuticals. Prior to joining Endo, Mr. Barry worked at Sanofi S.A. from 1992 until December 2016, holding roles of increasing responsibility in areas such as Sales Leadership, Commercial Operations, Marketing, Launch Planning and Training and Leadership Development. Most recently, he served at Sanofi S.A. as its General Manager and Head of North America General Medicines starting in September 2015 and as Vice President and Head of U.S. Specialty from April 2014 until August 2015. During this time, Mr. Barry oversaw three complex and diverse businesses with responsibility for leading sales and marketing activities for branded and generic products across the U.S. and Canada. He has a diverse therapeutic experience including aesthetics and dermatology, oncology, urology, orthopedics and medical device and surgical experience. He has an M.B.A. from Cornell University, Johnson School of Management and a B.A. in Public Relations and Marketing from McKendree University.

Mark Bradley

Mark_Bradley.jpgMark Bradley was appointed Executive Vice President and Chief Financial Officer, effective March 2020. He previously served as Senior Vice President, Corporate Development & Treasurer since June 2017. Mr. Bradley joined Endo in January 2007 as a Finance Director and has held various positions of increasing responsibility since joining the company. Prior to joining Endo, he spent nearly 7 years as a management consultant, most recently with Deloitte Consulting, providing a broad range of strategic and operational advice and services to senior executives across a number of industries. In addition, Mr. Bradley served as a Finance Director for an industrial products company for approximately 2 years. He spent the first 5 years of his career in public accounting at Ernst & Young LLP and received his CPA in October 1993. Mr. Bradley holds a Bachelor of Science degree in Accounting from Saint Joseph's University and a Master of Business Administration from The University of Texas at Austin.

Domenico Ciarico

Domenico CiaricoDomenico Ciarico was appointed Executive Vice President and Chief Commercial Officer, Sterile and Generics, effective August 2019. In this role, Mr. Ciarico leads Endo’s U.S. Generics business including responsibility and oversight of Par Generic and Par Sterile sales teams, commercial operations, marketing and business analytics group. Mr. Ciarico joined Par in July 2018 as SVP and General Manager of Par Sterile Products, responsible for all sales, marketing, pricing and portfolio management for PSP. Prior to joining Endo in 2018, Mr. Ciarico was with AmerisourceBergen Corporation (ABC) for over 20 years from May 1996 to July 2017 where he held several roles of increasing responsibility, including SVP of Health Systems, leading health systems sales and commercial strategy. Prior to that, Mr. Ciarico was Group Vice President, managing three of ABC’s service businesses: American Health Packaging, Pharmacy Healthcare Solution and AmerisourceBergen Technology Group, as well as other key leadership positions in operations and sales. Mr. Ciarico holds an M.B.A. and a B.S. degree from The Ohio State University.

Terrance J. Coughlin

Terry_Coughlin.jpgTerrance J. Coughlin was appointed Executive Vice President and Chief Operating Officer, effective November 2016. In this role, Mr. Coughlin has responsibility for Manufacturing and Technical Operations and R&D across the enterprise. Most recently, Mr. Coughlin served as Vice President, Operations of Par Pharmaceutical Companies, Inc., a subsidiary of Endo. Prior to Endo’s acquisition of Par in September 2015, Mr. Coughlin was the Chief Operating Officer of Par Pharmaceutical Companies, Inc. Prior to joining Par, Mr. Coughlin held numerous leadership roles with Glenmark Generics, Inc. USA/Glenmark Generics Limited, most recently having served as the President and Chief Executive Officer of Glenmark Generics, Inc. USA/Glenmark Generics Limited. Prior to this, Mr. Coughlin had the overall responsibility for Glenmark’s North American, Western European and Eastern European generics businesses, as well as its global active pharmaceutical ingredient business and generics operations in India. Prior to joining Glenmark, Mr. Coughlin served as Senior Vice President at Dr. Reddy’s Laboratories, Inc. Mr. Coughlin began his career in 1988 with Wyckoff Chemical Company, Inc. Mr. Coughlin earned a B.S. in chemistry from Central Michigan University.

Rahul Garella

Rahul_Garella.jpgRahul Garella was appointed Executive Vice President, International Pharmaceuticals, effective August 2019. In this role, he has responsibility for the overall strategic management and operations of Endo Ventures Limited, Ireland and commercial leadership for the International business which includes Paladin Labs, Canada and Global partnerships in the International markets. Mr. Garella joined Endo in 2014 as Senior Vice President. Mr. Garella has over 23 years’ experience in the pharmaceutical industry across branded and generic pharmaceuticals and APIs with international experience across the European, Asian and Latin America markets. Prior to joining Endo, Mr. Garella served as the Senior Vice President for Glenmark Pharmaceuticals Europe Limited responsible for building and managing their Western European business from 2008 until 2014 and their European and Latin American API business from 2005 until 2008. Previously, he worked with Ranbaxy in their Asia-Pacific division and Orchid Chemicals & Pharmaceuticals. He holds a Master of Business Administration (PGDBM) from the Institute of Management Technology, India as well as a Bachelor degree in Electrical Engineering from the Faculty of Engineering, Jamia Millia, New Delhi, India.

Matthew J. Maletta

Matt_Maletta.jpgMatthew J. Maletta was appointed Executive Vice President and Chief Legal Officer, effective May 2015, where he has global responsibility for all legal matters affecting the Company. Prior to joining Endo in 2015, Mr. Maletta served as Vice President, Associate General Counsel and Corporate Secretary of Allergan. In this position, he served as an advisor to the Chief Executive Officer and Board of Directors and supervised several large transactions, including the $70 billion acquisition of Allergan by Actavis in 2015. Mr. Maletta also played a key role defending Allergan from an unsolicited takeover bid by Valeant Pharmaceuticals and Pershing Square Capital Management in 2014. Mr. Maletta joined Allergan in 2002 and during his tenure, held roles of increased responsibility, including serving as the lead commercial attorney for Allergan’s aesthetics businesses for several years and as Head of Human Resources in 2010. Prior to joining Allergan, Mr. Maletta was in private practice, focusing on general corporate matters, finance, governance, securities and transactions. He holds a B.A. degree in political science from the University of Minnesota, summa cum laude and Phi Beta Kappa, and a J.D. degree, cum laude, from the University of Minnesota Law School.

Senior Management

Joseph A. Barbarite

Joe_Barbarite.jpgJoseph A. Barbarite is Executive Vice President, Global Quality and Compliance effective November 2016. He joined Endo in 2015 as the Senior Vice President, Global Quality and Compliance for Par Pharmaceutical, following Endo’s acquisition of Par. Mr. Barbarite brings over 35 years of pharmaceutical quality and compliance experience covering both generic and branded organizations. Prior to joining Par in 2004, he held leadership roles in Commercial and Pre-Commercial Quality at Forest Research Institute and Forest Laboratories, Inc. Prior to Forest Laboratories, he held management positions at Nycomed Inc. and at Sterling Winthrop Inc. Earlier in his career, Mr. Barbarite held QA auditing positions at Organon, Inc. and Altana, Inc. He started his career at Nice-Pak Products Inc. as the Quality Assurance Supervisor. Mr. Barbarite holds a Bachelor of Science in Biology from Fordham University as well as a Quality Engineer certification from the American Society for Quality.

Tracy Basso

Tracy BassoTracy Basso was appointed Chief Human Resources Officer effective July 1, 2019. In this role she leads all aspects of human resources in enabling the development and growth of Endo. Most recently Ms. Basso, who joined the company in November 2004, was Senior Vice President Human Resources, leading human resources support for the Company’s sterile injectable and generic businesses as well as operations, quality and enterprise-wide Talent Acquisition. Prior to joining the company, Ms. Basso, who has over 20 years of experience in human resources, worked for GlaxoSmithKline and started her career at Best Foods Baking Company. She holds a Master’s in Human Resources from Fordham University and a Bachelor of Arts in Business Management from Iona College.

Jack Boyle

Jack BoyleJack Boyle was appointed Senior Vice President, Controller and Chief Accounting officer, effective January 2020. Mr. Boyle joined Endo in 2007 as Financial Reporting Manager and assumed various roles of increasing responsibility, most recently serving as Senior Vice President, Financial Planning and Analysis since February 2018. Previously, he served as Vice President, Finance - Branded Pharmaceuticals from November 2016 until February 2018; Vice President, Finance for Endo’s International Unit from August 2014 until November 2016; Senior Director, FP&A from March 2011 until August 2014; and Director, Internal Audit from January 2008 until March 2011. Prior to joining Endo, Mr. Boyle served as a public accountant for Ernst & Young LLP from 1997 until 2007. Mr. Boyle is a licensed certified public accountant in the Commonwealth of Pennsylvania, and holds a Bachelor of Science degree in accounting from Bucknell University and an MBA from the Leonard N. Stern School of Business at New York University.

Laure Park

Laure Park Laure Park was appointed Senior Vice President, Investor Relations and Corporate Affairs effective August 2, 2018. In this role, Ms. Park is responsible for leading Endo’s Investor Relations and Corporate Affairs teams, including internal communications and engagement, as well as corporate communications and public relations. Prior to joining Endo, Ms. Park spent 23 years at Quest Diagnostics where she held key leadership roles in different functional areas including finance, investor relations and communications. Most recently, she served as Quest Diagnostics’ Vice President, Customer Experience, where she was responsible for building a customer-focused culture and representing the customer in the design and delivery of the customer experience. Prior to that, Ms. Park was Vice President of Communications & Investor Relations, responsible for leading investor relations and integrating it with the internal and external communications functions. She also served as the Vice President & General Manager of their Prescription Drug Monitoring business. Ms. Park began her career in public accounting with Deloitte & Touche in 1987. She is a member of the Healthcare Businesswomen’s Association (HBA), and holds bachelors' degrees in Accounting and Communications from the University of North Dakota.

Brandon Rockwell

Brandon_Rockwell.jpgBrandon Rockwell was appointed Senior Vice President of Business Development and Strategy effective March 2018. In his role, he has responsibility for the company-wide Business Development, Project Management, and Portfolio Management groups and plays an integral role in setting the strategic direction for the Company. Most recently, Mr. Rockwell served as Vice President of Business Development at Par Pharmaceutical.  Brandon had joined Par Pharmaceutical in 2007 and held key roles in setting the strategic direction of the company through the Par’s acquisitions and the integration of Qualitest and Par. In his tenure Mr. Rockwell has held a number of progressive leadership roles in business development, project management and information systems. Mr. Rockwell has a Bachelor of Science from Grove City College and a Master of Business Administration from New Jersey Institute of Technology.

Ruth Thorpe

Ruth ThorpeRuth Thorpe was appointed Senior Vice President, Information Technology and Chief Information Officer, effective August 2017. In this role, she has responsibility for the overall IT strategy and roadmap to support Endo's business strategy and vision, ensuring all global operations and end users are technology enabled. Prior to joining Endo, Ms. Thorpe was the Head of Global IT End User Services at Novartis, supporting 120,000 end users worldwide. While at Novartis, she also served as the US Head of Business Services, driving a multi-year transformation plan designed to deliver world-class Shared Business Support Services to Novartis’ US businesses. Prior to that, Ms. Thorpe held IT, Human Resources and Finance positions of increasing responsibility with Sanofi-Aventis US, Wyeth and SAP America. With more than 20 years of experience in the pharmaceutical industry, she has focused on the space where technology and business strategy converge to drive leading business performance. Ms. Thorpe is a recipient of several awards including the Young Women’s Christian Association’s Tribute to Women and Industry (TWIN) Award which honors women business leaders who have made significant contributions to their industries and professions, as well as the Healthcare Businesswomen’s Rising Star. In 2011, she was also named one of Computerworld’s 100 Premier IT Leaders. Ms. Thorpe is a veteran of the United States Air Force, and holds a Bachelor of Arts in Organizational Management from Cabrini College.

Susan Williamson

Susan WilliamsonSusan Williamson was appointed Senior Vice President and Chief Compliance Officer effective April 1, 2018. In this role, she is responsible for the strategic direction and operations of Endo's Global Corporate Compliance program. Ms. Williamson joined Endo in 2012 and has been a valued member of Endo's Corporate Compliance leadership team, previously serving as Endo's Vice President and U.S. and Canadian Compliance Officer where she was responsible for oversight of Endo's Corporate Compliance program including management of Endo's Corporate Integrity Agreement (CIA), enterprise wide corporate compliance training and monitoring and Aggregate Spend reporting. Prior to joining Endo, Ms. Williamson worked at Pfizer in Operational Risk Management supporting Pfizer's CIA from 2009 to 2012. Prior to her employment with Pfizer, Ms. Williamson spent over five years at Wyeth Pharmaceuticals and held key roles in building, developing and implementing a Global Corporate Compliance program. Ms. Williamson began her career in public accounting at Ernst & Young in the Assurance and Advisory Practice. Ms. Williamson is a Certified Public Accountant and holds a Bachelor of Science degree in Accounting from Saint Joseph's University as well as an M.B.A. from the Erivan K. Haub School of Business at St. Joseph's University.